Please ensure Javascript is enabled for purposes of website accessibility

Why BeyondSpring Stock Is Soaring This Week

By Cory Renauer – Aug 27, 2021 at 9:50AM

Key Points

  • BeyondSpring's lead candidate, plinabulin, attracted a big pharmaceutical partner to help with a potential new drug launch in China.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A lucrative partnership deal with a pharmaceutical giant in China bodes well for BeyondSpring's potential new blockbuster cancer drug.

What happened

Shares of BeyondSpring (BYSI -1.04%), a clinical-stage biotech company, have been surging this week in response to a lucrative new partnership with Jiangsu Hengrui Pharmaceuticals in China. Investors are justifiably excited about the partners' new agreement to commercialize and co-develop BeyondSpring's neutropenia-prevention candidate, called plinabulin.

By the time U.S. markets closed on Thursday, BeyondSpring's stock price had already climbed 49.4% from its closing price last Friday.

So what 

Chemotherapy kills cancer cells when it catches them trying to divide, but the ubiquitous class of treatments also makes it hard for bone marrow to produce enough white blood cells. This is why a granulocyte colony-stimulating factor G-CSF treatment from Amgen (AMGN 0.12%) called Neulasta was able to generate more than $2 billion in sales last year despite launching way back in 2002.

Smiling physician.

Image source: Getty Images.

While G-CSFs are a big help, white blood cell loss, or neutropenia, is still a huge challenge for oncologists and their patients. BeyondSpring's lead candidate, plinabulin, is a first-in-class drug that protects white blood cells from chemotherapy while leaving cancer cells vulnerable. 

Now what

The Food and Drug Administration is currently reviewing an application that could make plinabulin a treatment given to a huge cross-section of cancer patients undergoing chemotherapy. The agency is expected to announce an approval decision in November, and investors can reasonably expect a green light.

During clinical trials supporting the application, adding plinabulin to G-CSF dramatically reduced the risk of severe neutropenia. Just 0.9% of patients given plinabulin plus G-CSF ended up with severe neutropenia compared to 3.6% of the group randomized to receive G-CSF plus a placebo.

Neutropenia is a life-threatening condition on its own, plus it forces patients to suspend treatment, which allows disease to continue progressing. Plinabulin isn't getting a lot of attention from the wider investment community, but it's going to be impossible for oncologists to ignore the data. BeyondSpring's new tie-up with Hengrui, one of China's largest drugmakers, could also give plinabulin's potential launch a huge boost throughout that country. 

At its recent market cap of just $1.2 billion, BeyondSpring stock is trading at a fraction of sales expectations for plinabulin. There are no guarantees of success, but this stock looks well worth the risk at the moment.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BeyondSpring, Inc. Stock Quote
BeyondSpring, Inc.
$0.60 (-1.04%) $0.01
Amgen Stock Quote
$283.74 (0.12%) $0.34

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.